Approach to therapy of diffuse large B-cell lymphoma in the elderly: The International society of geriatric oncology (SIOG) expert position commentary Review uri icon


MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Geriatrics
  • Immunotherapy
  • Lymphoma, Large B-Cell, Diffuse
  • Medical Oncology


  • Diffuse large B-cell lymphoma (DLBCL) is a treatable and potentially curable malignancy that is increasing in prevalence in the elderly. Until recently, older patients with this malignancy were under-represented on clinical treatment trials, so optimal therapeutic approaches for these patients were generally extrapolated from the treatment of younger patients with this disorder. Because of heightened toxicity concerns, older patients were sometimes given reduced dose therapy, potentially negatively impacting outcome. Geriatric considerations including functional status and comorbidities often were not accounted for in treatment decisions. Because of these issues as well as the lack of treatment guidelines for the elderly population, the International Society of Geriatric Oncology convened an expert panel to review DLBCL treatment in the elderly and develop consensus guidelines for therapeutic approaches in this patient population. The following treatment guidelines address initial DLBCL therapy, in both limited and advanced stage disease, as well as approaches to the relapsed and refractory patient.

publication date

  • January 2015



  • Review



  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdv018

PubMed ID

  • 25635006

Additional Document Info

start page

  • 1058

end page

  • 68


  • 26


  • 6